Details of the Drug

General Information of Drug (ID: DMY0QL7)

Drug Name

Iomab-ACT

Indication

Disease Entry	ICD 11	Status	REF
B-cell acute lymphoblastic leukaemia	2B33.3	Phase 1	[1]
Diffuse large B-cell lymphoma	2A81	Phase 1	[1]
------------------------------------------------------------------------------------

Drug Type

Antibody

Cross-matching ID

Repurposed Drugs (RPD)

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Leukocyte common antigen (PTPRC)	TTUS45N	PTPRC_HUMAN	Inhibitor	[2]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

B-cell acute lymphoblastic leukaemia

ICD Disease Classification

2B33.3

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Leukocyte common antigen (PTPRC)	DTT	PTPRC	5.86E-05	-0.26	-0.36

Molecular Expression Atlas (MEA)

Jump to Detail Molecular Expression Atlas of This Drug

References

1	ClinicalTrials.gov (NCT04512716) Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma. U.S. National Institutes of Health.
2	Clinical pipeline report, company report or official report of Actinium Pharmaceuticals.